Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
Cash figures as of 2026-09-27. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Icotrokinra Phase 3 Positive · 2026-11-07
IL-23 · arthritis, psoriatic
Primary: American College of Rheumatology 20 (ACR20) response at Week 16 — 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16
· ACR50 at Week 16: 29% vs. 16% placebo
· ACR70 at Week 16: 13% vs. 5% placebo
· IGA 0/1 (clear or almost clear skin) at Week 16: 57% vs. 14% placebo (nominal p<0.001)
· PASI 90 at Week 16: 37% vs. 6% placebo (nominal p<0.001)
· Week 24: ACR20 69%, ACR50 40%, ACR70 18%
· Week 24 among patients with qualifying baseline skin involvement: IGA 0/1 64%, PASI 90 56%
Safety: Safety data through Week 24 were consistent with the established safety profile of ICOTYDE, with no new safety signals identified
Ustekinumab Phase 3 Positive · 2026-11-06
ICONIC-ASCEND
Guselkumab Phase 3 Positive · 2026-10-19
GALAXI / FUZION
Primary: Long-term maintenance efficacy in Crohn's disease: Week 144 (GALAXI long-term extension) clinical remission (CDAI <150) and endoscopic remission, and Week 48 (FUZION) combined fistula remission in Crohn's disease with perianal fistula — GALAXI Week 144 as-observed: clinical remission 94% (172/183) on guselkumab 100 mg q8w and 91% (185/204) on 200 mg q4w; endoscopic remission 52% (89/172) and 61% (119/195). FUZION Week 48 combined fistula remission: 35% in the 100 mg q8w group (up from 28% at Week 24) and 26% in the 200 mg q4w group (27% at Week 24)
· 90-day corticosteroid-free clinical remission at Week 144: 89% (162/183) on 100 mg q8w and 88% (179/204) on 200 mg q4w
· 74% (432/582) of guselkumab-treated GALAXI patients remained on treatment through three years (Week 144)
· FUZION: 90% of randomised patients, bio-naive and bio-experienced, completed treatment through Week 48
· FUZION randomised patients: n=113 (100 mg q8w maintenance) and n=115 (200 mg q4w maintenance), after 200 mg IV induction at Weeks 0, 4, 8
Safety: Safety findings through Week 144 (GALAXI) and Week 48 (FUZION) were consistent with the known safety profile of guselkumab in Crohn's disease; common adverse reactions include respiratory tract infections, diarrhoea, and injection site reactions
Talquetamab Phase 3 Positive · 2026-10-16
MonumenTAL-3 · relapsed or refractory multiple myeloma
Primary: Progression-free survival (PFS) for talquetamab plus daratumumab, with or without pomalidomide, versus daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma after at least one prior line of therapy (MonumenTAL-3, NCT05455320) — PFS hazard ratio 0.28 (95% CI 0.20-0.40, p<0.0001) for talquetamab-daratumumab-pomalidomide and HR 0.33 (95% CI 0.24-0.46, p<0.0001) for talquetamab-daratumumab versus the control arm, at a median follow-up of 24.6 months; 24-month PFS rates were 81.3% and 77.6% respectively
· Overall survival HR 0.47 (95% CI 0.30-0.73, p=0.0006) for the pomalidomide combination and HR 0.51 (95% CI 0.33-0.78, p=0.0015) for talquetamab-daratumumab; 24-month OS rates 89.2% and 87.9%
· Overall response rates 88.2% and 88.5% versus 77.6% for the control arm; complete response or better rates 71.1% and 68.9% versus 34.5%
· MRD-negative complete response or better rates (10-5, next-generation sequencing) 52.3% and 46.3% versus 15.9%
· N=864, all previously exposed to lenalidomide and a proteasome inhibitor; 85.1% refractory to lenalidomide and 93.4% refractory to their last line of therapy
· EMA CHMP recommended approval of the indication extension on October 16, 2026; European Commission approval is still pending
· Treatment discontinuations due to adverse events occurred in 10.5%, 8.0% and 6.7% of the three arms respectively
Safety: Safety profiles consistent with the known profiles of each monotherapy; Grade 3/4 treatment-emergent adverse events in 94.9% (pomalidomide combination), 74.8% (talquetamab-daratumumab) and 91.5% (control), with Grade 3/4 infection rates lowest on talquetamab-daratumumab at 29.2%
Guselkumab Dose 1 Phase 3 Mixed · 2026-10-12
crohn's disease
Primary: Clinical remission (CDAI score below 150) and endoscopic remission at Week 144 in the GALAXI 2/3 long-term extension — Clinical remission at Week 144 in 94% of patients on 100 mg every 8 weeks and 91% on 200 mg every 4 weeks (as-observed LTE analysis)
· 90-day corticosteroid-free clinical remission: 88% on both maintenance regimens at Week 144
· Endoscopic remission at Week 144: 52% on 100 mg q8w and 61% on 200 mg q4w
· 74% of treated patients remained on treatment through three years
· GALAXI program (NCT03466411): IV induction followed by subcutaneous maintenance in moderately to severely active Crohn's disease
· Week 144 results presented at the ACG 2026 Annual Scientific Meeting
Safety: Findings through Week 144 were consistent with the established TREMFYA safety profile in Crohn's disease